Recombinant human parathyroid hormone (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Recombinant human parathyroid hormone" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
low place
low place
11th place
8th place
low place
low place
doi.org
- Kim ES, Keating GM (July 2015). "Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism". Drugs. 75 (11): 1293–303. doi:10.1007/s40265-015-0438-2. PMID 26177893. S2CID 2074875.
- Watts NB, Bilezikian JP, Bone HG, Clarke BL, Denham D, Levine MA, et al. (March 2023). "Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism". Journal of the Endocrine Society. 7 (5): bvad043. doi:10.1210/jendso/bvad043. PMC 10119703. PMID 37091306.
europa.eu
ema.europa.eu
- "Preotact EPAR". European Medicines Agency. 17 September 2018. Retrieved 3 July 2020.
- "Natpar EPAR". European Medicines Agency. 18 December 2013. Retrieved 28 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
emea.europa.eu
- "Preotact: European Public Assessment Report". European Medicines Agency. 24 April 2006. Archived from the original on 22 June 2009. Retrieved 12 July 2009.
fda.gov
- "FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 30 January 2015. Retrieved 30 January 2015.
This article incorporates text from this source, which is in the public domain.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Kim ES, Keating GM (July 2015). "Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism". Drugs. 75 (11): 1293–303. doi:10.1007/s40265-015-0438-2. PMID 26177893. S2CID 2074875.
- Watts NB, Bilezikian JP, Bone HG, Clarke BL, Denham D, Levine MA, et al. (March 2023). "Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism". Journal of the Endocrine Society. 7 (5): bvad043. doi:10.1210/jendso/bvad043. PMC 10119703. PMID 37091306.
dailymed.nlm.nih.gov
- "Natpara (parathyroid hormone)- parathyroid hormone injection, powder, lyophilized, for solution". DailyMed. Retrieved 8 May 2021.
ncbi.nlm.nih.gov
- Watts NB, Bilezikian JP, Bone HG, Clarke BL, Denham D, Levine MA, et al. (March 2023). "Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism". Journal of the Endocrine Society. 7 (5): bvad043. doi:10.1210/jendso/bvad043. PMC 10119703. PMID 37091306.
pharmatimes.com
- PharmaTimes (13 June 2006). "NPS plummets on decision to halt Preos development - PharmaTimes". pharmatimes.com. Retrieved 24 April 2025.
semanticscholar.org
api.semanticscholar.org
takeda.com
- "Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate". www.takeda.com. Retrieved 24 April 2025.
- "Takeda to Discontinue Manufacturing of NATPAR® / NATPARA® for Patients with Hypoparathyroidism at the End of 2024". www.takeda.com. Retrieved 24 April 2025.
web.archive.org
- "FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 30 January 2015. Retrieved 30 January 2015. This article incorporates text from this source, which is in the public domain.
- "Preotact: European Public Assessment Report". European Medicines Agency. 24 April 2006. Archived from the original on 22 June 2009. Retrieved 12 July 2009.